Article Text

Protocol
Telehealth cancer-related fatigue clinic model for cancer survivors: a pilot randomised controlled trial protocol (the T-CRF trial)
  1. Rahul Ladwa1,2,
  2. Elizabeth P Pinkham1,3,
  3. Laisa Teleni2,
  4. Brigid Hanley4,
  5. Gemma Lock4,
  6. Jodie Nixon5,
  7. Oluwaseyifunmi Andi Agbejule6,
  8. Fiona Crawford-Williams2,6,
  9. Lee Jones2,
  10. Mark B Pinkham1,2,
  11. Jane Turner7,
  12. Patsy Yates1,2,
  13. Steven M McPhail2,8,
  14. Joanne F Aitken4,9,
  15. Carmen P Escalante10,
  16. Nicolas H Hart2,6,11,12,
  17. Raymond J Chan1,6
  1. 1 Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  2. 2 Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, Queensland, Australia
  3. 3 Physiotherapy Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  4. 4 Cancer Council Queensland, Brisbane, Queensland, Australia
  5. 5 Occupational Therapy Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  6. 6 Caring Futures Institute, Flinders University, Adelaide, South Australia, Australia
  7. 7 School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
  8. 8 Digital Health and Informatics, Metro South Health Service District, Brisbane, Queensland, Australia
  9. 9 School of Public Health, The University of Queensland, Brisbane, Queensland, Australia
  10. 10 The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  11. 11 Exercise Medicine Research Institute, Edith Cowan University, Perth, Western Australia, Australia
  12. 12 Institute for Health Research, The University of Notre Dame Australia, Perth, Western Australia, Australia
  1. Correspondence to Dr Nicolas H Hart; nicolas.hart{at}flinders.edu.au

Abstract

Introduction Cancer-related fatigue (CRF) is one of the most common and debilitating adverse effects of cancer and its treatment reported by cancer survivors. Physical activity, psychological interventions and management of concurrent symptoms have been shown to be effective in alleviating CRF. This pilot randomised controlled trial (RCT) will determine the feasibility of a telehealth CRF clinic intervention (T-CRF) to implement evidence-based strategies and assess the impact of the intervention on CRF and other clinical factors in comparison to usual care.

Methods and analysis A parallel-arm (intervention vs usual care) pilot RCT will be conducted at the Princess Alexandra Hospital in Queensland, Australia. Sixty cancer survivors aged 18 years and over, who report moderate or severe fatigue on the Brief Fatigue Inventory and meet other study criteria will be recruited. Participants will be randomised (1:1) to receive the T-CRF intervention or usual care (ie, specialist-led care, with a fatigue information booklet). The intervention is a 24-week programme of three telehealth nurse-led consultations and a personalised CRF management plan. The primary objective of this pilot RCT is to determine intervention feasibility, with a secondary objective to determine preliminary clinical efficacy. Feasibility outcomes include the identification of recruitment methods; recruitment rate and uptake; attrition; adherence; fidelity; apathy; and intervention functionality, acceptability and satisfaction. Clinical and resource use outcomes include cancer survivor fatigue, symptom burden, level of physical activity, productivity loss, hospital resource utilisation and carer’s fatigue and productivity loss. Descriptive statistics will be used to report on feasibility and process-related elements additional to clinical and resource outcomes.

Ethics and dissemination This trial is prospectively registered (ACTRN12620001334998). The study protocol has been approved by the Metro South Health and Hospital Services Human Research Ethics Committee (MSHHS HREC/2020/QMS/63495). Findings will be disseminated through peer-reviewed publications, national and international conferences and seminars or workshops.

Trial registration number Australian New Zealand Clinical Trials Registry ID: ACTRN12620001334998; Pre-results. Trial Version: Version 1.1. Last updated 10 December 2020.

  • Telemedicine
  • ONCOLOGY
  • COMPLEMENTARY MEDICINE
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Strengths and limitations of this study

  • This randomised controlled trial (RCT) assesses a ‘telehealth cancer-related fatigue clinic’ intervention embedded in the community setting as distinct from the clinical setting.

  • This feasibility pilot RCT study will provide data for an adequately powered effectiveness trial.

  • This study design will enable individualised treatment flexibility and compare interventions in a real-world community setting to realistically inform clinical and community practice directly.

  • This study is not powered to examine intervention efficacy and does not assess regionality.

  • Due to the nature of the intervention, blinding of the participants and treatment providers (cancer nurses and intervention physiotherapist) will not be possible.

Introduction

Background

Cancer-related fatigue (CRF) is one of the most common and debilitating adverse effects experienced by cancer survivors during and after cancer treatment,1 2 with two in three cancer survivors reporting some level of fatigue, and one in three cases assessed as severe.2 CRF differs to ‘normal’ fatigue as it cannot not be relieved through rest and sleep, and is defined as ‘a distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning’.1 While the exact mechanisms of CRF are unknown, its influence on the quality of life and functional capacity of cancer survivors is well established. CRF has long lasting negative impacts on the physical, mental, emotional and social well-being of people with cancer,3–9 often resulting in general weakness, diminished concentration or attention, emotional instability and decreased motivation or interest to engage in usual activities.1 10 CRF can also adversely affect the ability to return to work and engage in meaningful social relationships and leisure activities; negatively affecting cancer survivors’ mental health and quality of life.11 12 Moreover, CRF can influence a cancer survivor’s willingness to commence or continue with their cancer treatment, or their willingness and ability to attend follow-up appointments, potentially influencing treatment outcomes and survival.10 While the prevalence of CRF is high during active treatment, many cancer survivors also continue to report moderate to severe fatigue at 12 months post diagnosis and for several years after treatment completion.13 Additionally, caregivers of cancer survivors can also face significant emotional, physical, psychosocial and spiritual fatigue burden that affects their productivity, particularly while those they are caring for receive active treatment.11 14–17

Many studies have assessed pharmacological and non-pharmacological strategies to reduce CRF.13 Despite their prior use, pharmacological treatments (eg, modafinil, erythropoietin, methylphenidate) are largely ineffective for CRF, and may be potentially harmful to its users.18–20 Several guidelines, including the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for CRF, now recommend non-pharmacological treatments including physical activity (ie, aerobic exercise, resistance exercise, yoga), psychological interventions (ie, cognitive–behavioural therapy, psychoeducational therapy), physical therapies (ie, massage, acupuncture) and energy conservation techniques.1 10 A meta-analysis including 113 randomised clinical trials that involved 11 525 cancer survivors identified that exercise (weighted effect size (WES): 0.30; 95% CI 0.25 to 0.36; p<0.001), psychological (WES: 0.27; 95% CI 0.21 to 0.33; p<0.001) or combined (WES: 0.26; 95% CI 0.13 to 0.38; p<0.001) interventions as the most effective strategies for reducing CRF during and after cancer treatment when compared with pharmacologic interventions and other therapies.21 In addition, there is also recent evidence suggesting that the management of concurrent symptoms also improves CRF.22

Despite high-quality evidence of effective management strategies for CRF, it remains an unmet need for most cancer survivors, suggesting that current management strategies are not well implemented in clinical practice.1 2 A recent scoping review on the implementation of CRF management strategies into clinical practice identified a lack of high-quality studies in the literature which also highlights the disconnect between effective CRF interventions and routine clinical care.23 As a key implementation strategy, the concept of a ‘CRF clinic’ is one successful method to facilitate the systematic assessment and management of CRF in cancer survivors.24 25 These clinics are often physician-led, provided in well-resourced centres, and require cancer survivors to attend face-to-face appointments at the cancer centre.24 25 With CRF being one of the most common unmet needs reported by cancer survivors, it is key to develop and test more accessible and sustainable methods for delivering such CRF clinics. First, with the increasing use of telehealth, especially in the post-COVID era, it is extremely important to determine if a CRF clinic can be sufficiently delivered using telehealth.26 27 Second, trained cancer nurses28 are already managing a myriad of cancer symptoms and delivering psychological and physical activity interventions in their practice,29 which are key evidence-based strategies for managing CRF. Nurses in partnership with allied health practitioners, key members of multidisciplinary cancer care, are the ideal workforce to lead CRF clinics and enhance service accessibility, ultimately facilitating implementation of evidence-based care and improving CRF outcomes in cancer survivors.

Our pilot randomised controlled trial (RCT) seeks to determine the feasibility of a community-based and cancer nurse-led, telehealth CRF (T-CRF) intervention and assess the preliminary efficacy of the intervention on CRF and other clinical factors in comparison to usual care for cancer survivors and carers. Specifically, this trial will evaluate the feasibility of implementing the T-CRF intervention within the community setting into routine care by assessing recruitment, attrition, functionality, acceptability, satisfaction with care, adherence among participants and intervention fidelity among programme administrators. This trial will also evaluate the preliminary efficacy of the T-CRF intervention according to clinical and resource outcomes including cancer survivor fatigue, symptom burden, physical activity, productivity loss, hospital resource utilisation and carer fatigue and productivity loss. Preliminary efficacy data will be used to determine appropriate effect sizes and other statistical data that can be used in future statistical models to estimate sample sizes required to run the definitive clinical effectiveness trials.

Methods and analysis

Study design

A parallel-group, pilot RCT (1:1, intervention vs usual care) study design will be used to determine the feasibility and evaluate the preliminary efficacy of the T-CRF intervention. More specifically, this pilot RCT will provide feasibility and process data to inform the design of a fully powered RCT that will compare the effects of a novel clinic model of care verses usual care on the severity of CRF and related symptom outcomes. The pilot study design will incorporate individualised treatment flexibility in a real-world setting to provide realistic estimates of effects when implemented in the definitive RCT.30 The study protocol (v1.1) has been prepared in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement.31

Study setting

Cancer survivors and their carers will be recruited through outpatient clinics of the Division of Cancer Services at the Princess Alexandra Hospital (PAH), a tertiary hospital located in Brisbane, Queensland, Australia.

Participants

Eligibility criteria

Cancer survivors experiencing moderate to severe fatigue (ie, Brief Fatigue Inventory (BFI) score of 4 or greater32), and who are receiving cancer treatment at the PAH will be approached for recruitment. Eligible participants will be over 18 years of age and be at least 6 weeks post completion of primary cancer treatment (ie, surgery, radiotherapy, chemotherapy) or have completed at least 3 months of maintenance treatment (ie, hormone therapy, immunotherapy, chemotherapy). One informal carer of recruited cancer survivors will also be invited to participate if they are over 18 years of age. Further details of eligibility criteria for carers and cancer survivors are provided in table 1.

Table 1

Study eligibility criteria

Recruitment and consent

Potentially eligible cancer survivors will be identified and approached by their treating clinicians who will gauge their interest in the study, provide a study brochure and gain verbal consent to being approached by the research team. Cancer survivors will be contacted by a research team member, screened for eligibility and provided with study information. After a time of reflection (at least 24 hours), cancer survivors will be invited to sign a consent form (online supplemental material 1) to indicate their willingness to participate. At the time of consent, cancer survivor participants will be asked for their consent to contact their primary informal carer. Informal carers (individuals self-endorsed or identified by cancer survivors as a relative, friend or partner they have a close relationship with and who assists them with care) will be contacted by the research team, provided with study information and after a time of reflection (at least 24 hours), they will be invited to sign a consent form (online supplemental material 2) to indicate willingness to participate in the trial.

Supplemental material

Trial procedures

Sample size

Sixty cancer survivors experiencing moderate or severe fatigue (n=30 per arm) will be recruited. This study is not hypothesis testing; thus, power level is not the consideration underpinning sample size. Our chosen sample size for this study falls within the range of recommendations for preliminary studies of this nature.33 34 PAH service data indicate a throughput of more than 30 cancer survivors per week. Of these, approximately 30%–50% will report moderate-to-severe CRF.2 As our research team is embedded within the clinical care team at the PAH, we anticipate a high referral rate (~10 per week) and a recruitment rate of ~5 per week following full eligibility screening. All consented cancer survivors will be invited to refer their informal carer to participate in the trial. The sample size for informal carers is expected to be approximately 30, as we anticipate 50% of the carers referred by recruited cancer survivors will agree to participate in the study.

Randomisation and allocation

Randomisation occurs at the level of the cancer survivor participant. Carer participants are assigned to the same group as their cancer survivor. Computer-generated random numbers will be used to allocate cancer survivor participants in a 1:1 ratio by a researcher not involved in recruitment, intervention implementation or data collection. Allocation numbers will be sealed in opaque envelopes prepared by an independent researcher. Randomisation will be blocked using random permuted blocks of four and six to ensure that the groups are balanced periodically within stratification groups. To ensure equal distribution of participants with different levels of fatigue, participants will be stratified by their fatigue severity (moderate: 4–6 or severe 7–10 on the BFI scale) at baseline.

Blinding

Outcome assessors and data analysts will be blinded to group allocation. Participants will be advised not to reveal their group allocation to the outcome assessor. Due to the nature of intervention, trial participants and intervention administrators will not be blinded to group allocation.

Intervention

All participants will be provided with a written 3-page booklet on ‘Fatigue and Cancer’ published by Cancer Council Australia,35 regardless of arm assignment.

Arm 1: the T-CRF clinic (intervention)

The overarching aim of the intervention is to systematically implement evidence-based strategies including, but not limited to the promotion of physical activities/exercise intervention; delivery of psychological interventions; management of concurrent symptoms; and general coping. The design of the T-CRF clinic is informed by the NCCN CRF guidelines1 and incorporates CRF assessment, the development of management strategies, and the provision of referral pathways. Specific components of the T-CRF clinic intervention are listed in online supplemental material 3.

Briefly, after cancer survivor participant enrolment, nurses working at the non-government organisation Cancer Council Queensland (CCQ) will receive a referral from the research team indicating cancer survivor medical and treatment histories; fatigue severity; physical activity behaviours; nutritional status; any contraindications to unsupervised exercise recommendations; and a recommended clinic schedule at weeks 0–2, week 12–14 and week 24–26 post baseline (see figure 1). The CCQ nurse will contact cancer survivor participants directly to arrange three telehealth clinic appointments and four booster phone calls, two between each clinic appointment. During clinic consultations, nurses will: (1) conduct a CRF assessment; (2) provide verbal education on fatigue management addressing: physical activity, current symptoms and/or general coping; (3) codevelop a CRF management plan including up to three Specific, Measurable, Achievable, Relevant, and Time bound (SMART) goals that address physical activity, current symptoms and/or general coping; and (4) facilitate referrals. During consultations, CCQ nurses will be guided by a nurse clinic checklist that details the required components of each clinic session. Where referral pathways at PAH are not available or appropriate, CCQ nurses will refer cancer survivors to community organisations or to their primary care provider to coordinate community referrals. Cancer survivor participants will be emailed or posted a copy of their CRF management plan developed by the research team (see online supplemental material 4).

Figure 1

The telehealth cancer-related fatigue clinic model for cancer survivors follow-up. Schematic of the trial design. T1: baseline; T2: 12–14 weeks post baseline; T2: 24–26 weeks post baseline; T4: 48 weeks post baseline. T-CRF, telehealth cancer-related fatigue.

CCQ nurses will make general recommendations for exercise intensity levels and supervision based on an adapted clinical pathway triage algorithm developed by Stout et al 36 (figure 2). This decision-making support tool enables personalised condition assessment, risk stratification and referral to optimal settings for exercise promotion in cancer survivors—in this regard, to address CRF. Participants who require exercise supervision will be referred to the cancer physiotherapist of the PAH, who will offer face-to-face or telehealth group exercise sessions over 12 weeks (once weekly) or 6 weeks (twice weekly) or one-on-one exercise sessions including aerobic, resistance, flexibility and balance activities depending on individual need and available equipment. Face-to-face group exercise allows for eight participants supervised by two physiotherapists, and telehealth group exercise allows for five participants supervised by one physiotherapist. Attendance at supervised exercise sessions or referrals to community exercise programmes will be recorded as a measure of adherence to the intervention. Between the first and second T-CRF clinics, CCQ nurses will provide two 10–20 min follow-up booster phone calls to participants to monitor progress towards meeting SMART goals and offer support. Adherence to the intervention will be monitored using clinic and phone review checklists.

Figure 2

Algorithm for determining exercise intensity and levels of supervision. The pathway is intended to stratify individuals to higher (red), intermediate (yellow) or lower (green) condition complexity, which provides insight into the level of supervision and guidance that individuals may need to successfully engage in exercise and informs referrals. OPD, outpatient department; PAH, Princess Alexandra Hospital; YMCA, Young Men's Christian Association.

Intervention training and adverse events (AEs)

CCQ nurses have extensive experience in caring for cancer survivors. Intervention physiotherapists are nationally accredited by the Australian Physiotherapy Association and have extensive experience caring for cancer survivors. CCQ nurses will receive additional training with regards to all components of the T-CRF intervention. Briefly, training will comprise a written manual with information on how to deliver the intervention, and material on communication, motivational interviewing and cognitive behavioural techniques; and a 1-day workshop incorporating a mix of written mock intervention case studies and motivational interviewing role play activities.

Participants requiring supervised exercise require medical clearance from their treating oncology team and will undergo a comprehensive initial assessment with vital signs monitored pre and post exercise by the intervention physiotherapist to ensure safety. Procedural guidelines are in place to deal with unexpected exercise-related AEs as clinically indicated. Existing incident reporting structures at the PAH will be followed and the participant’s treating clinician, cancer nurse coordinator and CCQ intervention nurses will be informed. A detailed review of cancer survivor participant assessment forms and exercise history will be undertaken by an independent oncologist. For participants who experience any emotional distress during CCQ intervention nurse consults will be referred to the CCQ counselling service consisting of nurse counsellors and psychologists for evaluation and clinical management.

Intervention fidelity

In addition to the use of clinic and phone booster checklists, participants and CCQ nurses will be asked to consent to the audio recording of all nurse-led clinics for quality assurance and to recheck any data or information. Fidelity of the intervention will be assessed using the framework for behavioural interventions recommended by the National Institutes of Health37 38 as outlined in table 2. It is expected that some of these strategies will be refined through the conduct of the pilot trial.

Table 2

Intervention fidelity strategies

Arm 2: control (usual care)

The control arm consists of usual follow-up care plus a written 3-page booklet on Fatigue and Cancer published by Cancer Council Australia.35 Follow-up arrangements at the PAH will vary primarily according to cancer type, and is determined by the treating surgeon, medical oncologist or radiation oncologist through a specialist-led model.

Baseline and follow-up procedures

Study schedules for data collection and a schematic of the trial design are shown in table 3 and figure 1, respectively. Clinical characteristics and demographics (ie, age, gender, ethnicity, highest level of education, living arrangements, marital status, employment) will be collected directly from participants and medical records by outcome assessors at baseline (T1). All participant-reported outcomes will be collected at baseline (T1), 12–14 weeks (T2), 24–26 weeks (T3) and 48 weeks (T4) post baseline. Instruments will be self-administered via online surveys using Research Electronic Data Capture (REDCap) or interviewer-administered by blinded outcome assessors via telephone. Participants and healthcare providers will be invited to opt into a semistructured interview at T4 either face to face, by telephone or through videoconferencing as per interviewee preference. Semistructured interviews will be used to collect data on intervention functionality, acceptability and satisfaction that will be guided by the Consolidated Framework for Implementation Research (CFIR) (see online supplemental material 5 for the interview guide).

Table 3

Study schedule for data collection

Outcomes

Primary outcomes include measurements relevant to the feasibility of conducting large-scale RCT. Secondary outcomes involve measurements of preliminary clinical efficacy intended for use in the full-scale trial.

Trial feasibility

Feasibility of the T-CRF trial is the primary outcome of this pilot RCT and will be assessed using the following process outcomes: recruitment and uptake, attrition, adherence, fidelity, apathy, functionality, acceptability and satisfaction with the intervention (see table 4).

Table 4

Study outcome measures

Recruitment, intervention uptake and attrition will be assessed using screening logs and online REDCap survey data. Intervention adherence and fidelity of intervention nurses will be evaluated through assessing the number of items completed on the nurse-clinic checklist during consultations and booster phone calls. Apathy will be measured using the Self-Reported Apathy Evaluation Scale.39 Intervention functionality, acceptability and satisfaction will be evaluated using a cancer survivor satisfaction survey as well as stakeholder semistructured interviews. Semistructured interviews will be conducted with intervention nurses and other healthcare providers involved in providing care for cancer survivor participants. Cancer survivors and carers allocated to the T-CRF trial arm will be invited to participate in an interview at the 12-month time point. Guiding questions (see online supplemental file 5) and analysis of the interviews will be guided by the CFIR.

Clinical outcomes

A secondary goal is to assess the preliminary efficacy of the T-CRF intervention on cancer survivor’s fatigue, symptom burden, productivity loss, hospital resource utilisation, level of physical activity, as well as carer’s fatigue, and carer’s productivity loss. These outcomes will be assessed using validated self-report measures and medical record data as described in table 3. Additionally, participants will be required to wear a Garmin wrist-worn activity monitoring device at no additional cost. This will measure physical activity (pedometer: number of steps per day, altimeter: number of stairs climbed, total hours doing moderate intensity exercise based on heart rate per day and total hours slept per day).

Withdrawal and study termination

Any participant can withdraw from the study at any time and for any reason without prejudice. If a cancer survivor or carer participant is withdrawn because of an AE, the investigator will arrange for appropriate follow-up care until the AE is resolved or has stabilised. Unresolved AEs will be followed until the last scheduled follow-up visit or until no longer indicated, per investigator discretion. In addition to AEs, other reasons for removal of participants from the study might include, but are not limited to, withdrawal of consent, administrative decision by the principal investigator or responsible organisation, or protocol deviation. If a participant asks or decides to withdraw, all efforts will be made to complete and report the observations, especially primary and secondary objectives, as thoroughly as possible up to the date of withdrawal. The primary reason for withdrawal (where known) will be identified and recorded on a case report form, along with the date of withdrawal. Withdrawal criteria are listed in table 1.

Statistical analysis

Descriptive statistics will be used to report on feasibility and process-related outcomes (eg, recruitment rate, retention and attrition rates, adherence) as well as clinical and resource-use outcomes (eg, fatigue, physical activity, hospital resource utilisation). Preliminary effect size estimates for cancer survivor and resource use outcomes will be calculated following intention-to-treat principles using linear mixed models to account for repeated measures and missing data. Effect sizes will be reported as estimates with a 95% CI, and without p values due to the underpowered nature of the study. Models will include group, time and their interaction and be adjusted by fatigue severity and current cancer treatment. Balance of demographic variables between the usual care and intervention group will be examined and adjusted for potential confounders. Assumptions of all models (normality, linearity, homoscedasticity) will be examined using the residuals of the model and will be described using mean, median, skewness, kurtosis and plots such as histograms and QQ-plots. If assumptions are violated, models will be either bootstrapped or log transformed, as appropriate. Missing data will be explored using descriptive statistics. Generalised linear models will be used to provide estimates for categorical outcomes such as adherence, with appropriate link models used based on the outcome distribution. All statistical analysis will be undertaken by an independent statistician blinded to treatment allocation. Semistructured interviews will be audio or video recorded and will be transcribed verbatim for thematic analysis; a method for systematically identifying, organising and offering insight into, patterns of meaning (themes) across a dataset.40

Data management

Data management and confidentiality

All data will be recorded in electronic case report forms. Participants will only be identified by a unique participant study number on the case report forms and other documents. A secure system for online and offline data capture will be used for direct data entry by both participants and research staff. Case report forms will be accessed by the project manager for data checking. Data queries will be generated and sent to the relevant research team member for response before the database is locked and released for statistical analysis. Other study-related documents (eg, signed informed Participant Information and Consent Form (PICF)) will be kept in strict confidence by the Chief Investigator.

Data checking

Data will be directly entered into REDCap by members of the research team using a tablet or desktop computer. All research team members will receive training regarding data collection from the Project Manager. To maximise data integrity and completeness, the project manager will undertake routine audits with data validation performed via REDCap. Any discrepancies and missing data will be alerted and resolved with the relevant research team member(s) as soon as practical. All electronic case report forms will be maintained on the system with details of any changes logged accordingly.

Data protection

Participants will be informed that data will be archived at PAH and that these data may be viewed by staff including the project manager and by external auditors on behalf of PAH and appropriate regulatory authorities including Metro South Health Human Research Ethics Committee (MSH HREC) and PAH Research Governance. Participants will be informed that a study report will be submitted to regulatory authorities and for publication and conference presentation. However, participants will be deidentified in such reports with only their study identification number, gender and age used for recording or linkage purposes.

Data retention

Audio and video recordings of the telehealth intervention will be stored electronically at Queensland University of Technology in a secure repository and will be securely destroyed after analysis is conducted. All other source data, clinical records and laboratory data relating to the study will be archived at PAH for at least 15 years after study completion and remain available for retrospective review or audit. The investigator and study staff will be responsible for maintaining a comprehensive filing system of all essential study-related documentation. All essential documentation will be retained by PAH as per the requirements of the responsible organisation for the same period required for medical records retention. No study document will be destroyed without written agreement between the PAH and the principal investigator. If the principal investigator wishes to assign the study records to another party or move them to another location, they will notify the responsible organisation in writing of the new responsible person or the new location.

Patient and public involvement

To ensure cancer survivor perspectives were represented and accommodated in the intervention design and implementation, the patient support and advocacy group at CCQ were invited, have provided input into the study. Consumers were invited to provide comments and critical appraisal of the study protocol. They will also assist with raising the profile of the study through their consumer and clinical networks. CCQ will also be providing the intervention cancer nurses who will deliver the T-CRF clinics.

Ethics and dissemination

Prior to the commencement of the study, written approval was acquired by MSH HREC (ID: HREC/2020/QMS/63495), with Research Governance approval provided by the PAH Research Governance Office. This study will be conducted in accordance with the principles of the Declaration of Helsinki,41 Good Clinical Practice (CPMP/ICH/135/95)42 and the National Health and Medical Research Council National Statement on Ethical Conduct in Research Involving Humans.43

Archiving and regulatory inspection

In accordance with the guidance on Good Clinical Practice (GCP), this study may be selected for audit. Inspection of site facilities and review of study-related records may occur by a representative of the responsible organisation or regulatory authority to evaluate the study conduct and compliance with the protocol, GCP and applicable regulatory requirements. All study-related documents and records will be retained for a minimum of 15 years after trial completion. Written agreement from the responsible organisation will precede destruction of the same.

Dissemination

Publication and reporting of results and outcomes of this trial will be accurate and honest, undertaken with integrity and transparency. Trial results will be disseminated to all participants with a summary sheet that will outline the trial findings in lay language. It is intended that the findings from this trial will be disseminated at academic, clinical and professional conferences, and published in high-quality, international peer-reviewed journals.

Protocol amendments and deviation

Neither the principal investigator nor the PAH will modify or alter this protocol without the agreement of the other. All agreed protocol amendments will be clearly recorded on a protocol amendment form and will be signed and dated by the original protocol approving signatories. All protocol amendments will be submitted to the MSH HREC for approval before implementation. The only exception will be when the amendment is necessary to eliminate an immediate hazard to the trial participants. In this case, the necessary action will be taken first, with the relevant protocol amendment following shortly thereafter. Should any protocol deviation occur, it will be reported to the study project manager as soon as is practical. The deviation and the reason for its occurrence will be included in the study report.

Trial status

This protocol (V.1.1) was approved and registered on the Australian New Zealand Clinical Trial Registry (ANZCTR) on the 10 December 2020 (ID: ACTRN12620001334998). The study started recruitment on 17 February 2021, and as of 1 November 2021, 40 cancer survivor participants and 16 carers have been enrolled. Data collection is anticipated to conclude in January 2023 (48 weeks following the final participant enrolled). Data analysis and manuscript preparation are anticipated to occur over 6 months, concluding in July 2023.

Ethics statements

Patient consent for publication

Acknowledgments

The authors wish to acknowledge Cancer Council Queensland who have provided feedback on the study and contributed their telehealth facilities and the cancer nurses who will be delivering the intervention.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • NHH and RJC are joint senior authors.

  • Twitter @Fiona_CW1, @DrNicolasHart, @rayychan

  • Contributors RJC and RL conceptualised the study. RJC, RL, PY, SMM, CPE, JFA MBP, BH, and GL acquired and received the funding. JT, BH, JFA provided input on motivational interviewing, counselling techniques, and resources for the nurse-led intervention. OAA, EPP, JN, LT, FCW and NHH led the design, development, and writing of the pilot RCT protocol. LJ provided data and statistical analysis methods. All authors contributed important intellectual content to the trial design and written protocol and reviewed and approved the final version for publication.

  • Funding This work is financially supported by the Princess Alexandra Research Foundation (Award Number: RSS_2020_095). RJC (#1194051), PY (#2009529), and SMM (#1161138) receive salary support from National Health and Medical Research Council administered fellowships. The funding bodies have no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.